Bristol Myers Squibb & Merck & Co.

Bristol Myers Squibb: Bristol Myers Squibb>>>'s immunotherapies Opdivo and Yervoy are mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.

Merck & Co.: Merck & Co.>>>'s immunotherapy Keytruda is mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.

Bristol Myers Squibb: Bristol Myers Squibb is participating in the Kinaxis conference as a speaker, sharing insights on navigating disruption and improving operational outcomes in supply chain management.

Merck & Co.: Merck is participating in the Kinaxis conference as a speaker, sharing insights on navigating disruption and improving operational outcomes in supply chain management.

Merck & Co.: Merck & Co. struck a deal to cut prices, committing to sell its diabetes drugs Januvia, Janumet, and Janumet XR at 70% off list prices directly to US consumers and pledging $70 billion in US R&D and manufacturing investments.